Bladder Cancer

>

Latest News

Stable Health, Function in BCG-Unresponsive NMIBC With N-803 Plus BCG
Stable Health, Function in BCG-Unresponsive NMIBC With N-803 Plus BCG

February 6th 2024

Available data on patient-reported outcomes and positive interim results from QUILT 3.032 support N-803 for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.

Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG
Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG

February 2nd 2024

Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC
Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC

January 30th 2024

Genitourinary Cancers Symposium Roundup: A Comprehensive Overview
Genitourinary Cancers Symposium Roundup: A Comprehensive Overview

January 29th 2024

Adjuvant Pembrolizumab Shows Clinically Significant DFS Benefit in Urothelial Carcinoma
Adjuvant Pembrolizumab Shows Clinically Significant DFS Benefit in Urothelial Carcinoma

January 27th 2024

More News